Ringin, Elysha
Dunstan, David W.
McIntyre, Roger S.
Berk, Michael
Owen, Neville
Rossell, Susan L.
Van Rheenen, Tamsyn E.
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (GNT1078360, GNT1156072, GNT1003960, GNT1154651, GNT1088785)
Article History
Received: 18 July 2022
Revised: 14 September 2022
Accepted: 27 September 2022
First Online: 15 October 2022
Competing interests
: Professor McIntyre has received research grant support from CIHR/GACD/Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Professor McIntyre is the CEO of Braxia Scientific Corp. Elysha Ringin, Prof Dunstan, Prof Berk, Prof Owen, Prof Rossell, and Dr Van Rheenen have nothing to disclose.